Form 8-K - Current report:
SEC Accession No. 0001789769-24-000106
Filing Date
2024-12-23
Accepted
2024-12-23 17:00:31
Documents
13
Period of Report
2024-12-20
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant

Document Format Files

Seq Description Document Type Size
1 8-K til-20241220.htm   iXBRL 8-K 34681
  Complete submission text file 0001789769-24-000106.txt   163112

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT til-20241220.xsd EX-101.SCH 1773
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT til-20241220_lab.xml EX-101.LAB 22530
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT til-20241220_pre.xml EX-101.PRE 13038
15 EXTRACTED XBRL INSTANCE DOCUMENT til-20241220_htm.xml XML 2804
Mailing Address 3963 MAPLE AVENUE SUITE 350 DALLAS TX 75219
Business Address 3963 MAPLE AVENUE SUITE 350 DALLAS TX 75219 (972) 499-3350
Instil Bio, Inc. (Filer) CIK: 0001789769 (see all company filings)

EIN.: 832072195 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40215 | Film No.: 241574687
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)